Tesaro raises $100.8 million in follow-on

Tesaro Inc. (NASDAQ:TSRO) raised $100.8 million through the sale of 3.2 million shares at $31.50 in a follow-on underwritten by Citigroup; Deutsche Bank; Leerink; BMO Capital Markets; and Baird. Tesaro proposed to raise up to $100 million in the offering late Tuesday, when its share price was $33.63. The company plans to submit an NDA to FDA by mid-year for rolapitant to prevent chemotherapy-induced nausea and vomiting (CINV). Tesaro has exclusive, worldwide rights to develop and commercialize the neurokinin 1 (NK1) Substance P receptor (TACR1) antagonist from Opko Health Inc. (NYSE:OPK; Tel Aviv:OPK) (see BioCentury Extra, Dec. 23, 2013). ...